Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023

• 2023

  Log in to bookmark this resource.

  Log in
• Jefferson Jones; Katherine Fleming-Dutra; Mila Prill; Lauren Roper; Oliver Brooks; Pablo Sánchez
PMID: 37616235DOI: https://dx.doi.org/10.15585/mmwr.mm7234a4

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article describes the use of nirsevimab, a new drug approved in 2023, to prevent severe respiratory syncytial virus (RSV) disease in infants and young children. Nirsevimab is given as an injection before or during the RSV season. It is recommended for babies under 8 months old entering their first RSV season and for those aged 8-19 months at high risk entering their second season. The drug has shown good results in trials, reducing hospital visits due to RSV. However, it should not be used by children with certain allergies or bleeding disorders without caution.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Immunization; Infant; Respiratory Syncytial Virus Infections; United States; Advisory Committees; Immunization Programs; Respiratory Syncytial Virus, Human; Antibodies, Monoclonal, Humanized

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF Diarrheal Deaths After the Introduction of Rotavirus Vaccination in 4 Countries 2021 · Universidad de Cartagena, Centers for Disease Control and Prevention (CDC), Universidad de Santiago de Chile, Pan American Health Organization, Universidad Nacional de Colombia

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---